Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Off-target messenger RNAs of the G13 short hairpin RNA (shG13) refer to a broad set of cellular transcripts that are unintentionally silenced by a specific shRNA sequence originally designed to target the Gnas gene. In landmark studies of RNA interference (RNAi) safety, shG13 was identified as a potent inducer of neurotoxicity in the mammalian brain due to its 'seed-based' off-target effects (Boudreau et al., 2009). The guide strand of shG13 possesses a seed sequence (nucleotides 2-8) that is complementary to the 3' untranslated regions (UTRs) of many essential mRNAs, leading to their unintended degradation via a mechanism similar to endogenous microRNAs. This off-target activity can cause severe phenotypic changes, including neuronal loss and motor deficits, which are independent of the intended silencing of the primary target gene. Consequently, these off-target mRNAs are not therapeutic targets themselves but represent a major safety hurdle in the development of shRNA-based gene therapies. Research into these interactions has led to the development of improved RNAi platforms, such as artificial microRNAs (miRNAs), which reduce off-target signatures and improve safety profiles (McBride et al., 2008).
The G13 shRNA guide strand, once processed by Dicer and loaded into the RNA-induced silencing complex (RISC), utilizes its seed region (nucleotides 2-8) to recognize and bind to partially complementary sequences in the 3' untranslated regions (UTRs) of various off-target mRNAs, triggering mRNA destabilization and translational inhibition (Boudreau et al., 2009; PubMed: 19352365).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Off-target messenger RNAs of G13 short hairpin RNA (shG13 off-targets).